Evaluation of the efficacy of chemotherapy regimen with Taxane in combination with Trastuzumab biosimilars in preoperative treatment of HER2- positive breast cancer
Tóm tắt
Aims: To evaluate the overall response rate (ORR) and pathological complete response (pCR). Identify side effects of biosimilar trastuzumab in combination with taxane-based chemotherapy for patients with HER2- positive breast cancer.
Methods: Retrospective study of cases with HER2 (+) breast cancer, stage II-III-IV treated with biosimilar trastuzumab 8mg/kg at the first cycle, then following 6 mg/kg) in combination with taxane-based chemotherapy (TCH regimen including: Docetaxel 75mg/m2 with or without Carboplatin AUC 6, or AC – TH (P) regimen including: Doxorubicin 60 mg/m2, Cyclophosphamide 600 mg/m2 – Docetaxel 100mg/m2 with or without Pertuzumab 840 mg at the first cycle, then following 420 mg) at HCM city Oncology hospital from 01/01/2022-31/12/2022. Re-evalutaion for surgery is done after 6 cycles.
Results: The overall response rate was 95.7%, with a clinical partial response rate of 78.9% and a complete response rate of 16.8%. The pathological complete response rate was 49.5%. Side effects were controlled: no cases of congestive heart failure were reported, and 3.4% of cases developed grade 4 febrile neutropenia.
Conclusion: Biosimilar trastuzumab in combination with taxane-based chemotherapy for patients with HER2-positive breast cancer demonstrates a significant complete response rate with well-controlled toxicities.
DOI: 10.59715/pntjmp.4.3.3
